MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fantz, C.
Right arrow Articles by Spencer, H. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fantz, C.
Right arrow Articles by Spencer, H. T.

Vol. 57, Issue 2, 359-366, February 2000

Drug-Resistant Variants of Escherichia coli Thymidylate Synthase: Effects of Substitutions at Pro-254

Corinne Fantz, David Shaw, William Jennings, Antonia Forsthoefel, Maria Kitchens, Jason Phan, Wladek Minor, Lukasz Lebioda, Franklin G. Berger, and H. Trent Spencer

Departments of Biological Sciences (D.S., W.J., A.F., M.K., F.G.B., H.T.S.) and Chemistry and Biochemistry (C.F., J.P., L.L.), University of South Carolina and the South Carolina Cancer Center (H.T.S.), Columbia, South Carolina; and Department of Molecular Pharmacology and Biophysics (W.M.), University of Virginia, Charlottesville, Virginia.

Drug-resistant variants of thymidylate synthase (TS) can potentially be used in gene therapy applications to decrease the myelosuppressive side effects of TS-directed anticancer agents or to select genetically modified cells in vivo. Mutations of proline 303 of human TS confer resistance to TS-directed fluoropyrimidines and antifolates (Kitchens et al., 1999). We generated the corresponding variants in Escherichia coli TS (ecTS), position 254, to better understand the mechanism by which mutations at this residue confer resistance. In addition, because ecTS is intrinsically resistant to several antifolates when compared with human TS, we suspected that greater resistance could be achieved with the bacterial enzyme. The P254L enzyme conferred >100-fold resistance to both raltitrexed and 5-fluoro-2'-deoxyuridine (FdUrd) compared with wild-type ecTS. Four additional mutants (P254F, P254S, P254G, and P254D), each of which complemented growth of a TS-deficient cell line, were generated, isolated, and characterized. Steady-state values of Km for dUMP and kcat were not substantially different among the variants and were comparable with the wild-type values, but Km for methylenetetrahydrofolate (CH2H4PteGlu) was >10-fold higher for P254D. Values of kon and koff for nucleotide binding, which were obtained by stopped-flow spectroscopy, were virtually unchanged among the mutants. Drastic differences were observed for CH2H4PteGlu binding, with Kd values >15-fold higher than observed with the wild-type enzyme; surprisingly, the proposed isomerization reaction that is very evident for the wild-type enzyme is not observed with P254S. The decrease in affinity for CH2H4PteGlu correlates well with Ki values obtained for three TS-directed inhibitors. These results show that mutations at Pro-254 specifically affect the initial binding interactions between enzyme and cofactor and also alter the ability of the mutant enzymes to undergo conformational changes that occur on ternary complex formation. The crystal structure of P254S was determined at 1.5 Å resolution and is the most precise structure of TS available. When compared with wild-type TS, the structure shows local conformational changes affecting mostly Asp-253; its carbonyl is rotated approximately 40°, and the side chain forms an ion pair with Arg-225.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics